Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2003-12-23
2008-10-14
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S139100, C424S141100, C424S145100, C530S387300, C530S388250
Reexamination Certificate
active
07435413
ABSTRACT:
The invention concerns anti-tissue factor (anti-TF) antibodies with enhanced anticoagulant potency, and methods and means for identifying, producing and using such antibodies. The anti-TF antibodies of the present invention are designed to comprise a region binding to an epitope in the C-terminal macromolecular substrate binding region of TF.
REFERENCES:
patent: 5223427 (1993-06-01), Edgington et al.
patent: 5437864 (1995-08-01), Edgington et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5811248 (1998-09-01), Ditlow et al.
patent: 5986065 (1999-11-01), Wong et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6087487 (2000-07-01), Vlasuk et al.
patent: 6274142 (2001-08-01), O'Brien et al.
patent: 6555319 (2003-04-01), Wong et al.
patent: 6703494 (2004-03-01), Kirchhofer et al.
patent: 6986894 (2006-01-01), O'Brien et al.
patent: 2004/0229282 (2004-11-01), Wong et al.
patent: 2005/0089929 (2005-04-01), Jiao et al.
patent: 2005/0271664 (2005-12-01), Wong et al.
patent: 2006/0039901 (2006-02-01), Jiao et al.
patent: 2006/0159675 (2006-07-01), Jiao et al.
patent: 2006/0235209 (2006-10-01), Jiao et al.
patent: 266993 (1988-05-01), None
patent: 278776 (1988-08-01), None
patent: 0 420 937 (1991-04-01), None
patent: 1 069 185 (2001-01-01), None
patent: 1222854 (2002-07-01), None
patent: WO-88/09817 (1988-12-01), None
patent: WO-89/12463 (1989-12-01), None
patent: WO 96/40921 (1996-12-01), None
patent: WO-98/40408 (1998-09-01), None
patent: WO 99/51743 (1999-10-01), None
patent: WO-01/70984 (2001-09-01), None
patent: WO-01/70984 (2001-09-01), None
patent: WO-03/037911 (2003-05-01), None
patent: WO-03/037911 (2003-05-01), None
patent: WO-03/103711 (2003-12-01), None
patent: WO-2005/000896 (2005-01-01), None
patent: WO-2005/000896 (2005-01-01), None
patent: WO-2005/004793 (2005-01-01), None
patent: WO-2005/004793 (2005-01-01), None
Janeway et al. Immunobiology, third edition, Garland Publishing Inc. (1999), pp. 3:1 to 3:11.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity” (1982) Proc Natl Acad Sci USA 79:1979-1983.
Addonizio et al., “Preliminary characterization of the procoagulant material in human ascites”Surgery101(6):753-762 (Jun. 1987).
Albrecht et al., “An ELISA for tissue factor using monoclonal antibodies”Blood Coagulation and Fibrinolysis3:263-270 (1992).
Andrews et al., “Conservation of tissue factor primary sequence among three mammalian species”Gene98:265-269 (1991).
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”Molecular Immunology30(1):105-108 (Jan. 1993).
Bach et al., “Purification and Characterization of Bovine Tissue Factor”Journal of Biological Chemistry256(16):8324-8331 (1981).
Badimon et al., “Hirudin and Other Thrombin Inhibitors: Experimental Results and Potential Clinical Applications”Trends Cardiovasc. Med.1(6):261-267 (1991).
Banner et al., “The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor”Nature380:41-46 (1996).
Barker, P. L. et al., “Cyclic RGD Peptide Analogues as Antiplatelet Antithrombotics”Journal Medicinal Chemistry35:2040-2048 (1992).
Bjorklid et al., “Purification and Some Properties of the Protein Component of Tissue Thromboplastin from Human Brain”Biochemical Journal165(1):89-96 (1977).
Bloom et al., “Intrachain disulfide bond in the core hinge region of human IgG4”Protein Science6:407-415 (1997).
Bom et al., “Application of Factor VII-Sepharose Affinity Chromatography in the Purification of Human Tissue Factor Apoprotein”Thrombosis Research42:635-643 (1986).
Bone, R. C., “Modulators of Coagulation: A Critical Appraisal of Their Role In Sepsis”Arch Intern Med152:1381-1389 (1992).
Braunwald et al., “ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction”Journal of the American College of Cardiology36(3):970-1056 (Sep. 2000).
Bromberg et al., “Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation”Proc. Natl. Acad. Sci.USA 92:8205-8209 (Aug. 1995).
Broze, Jr., et al., “Purification of Human Brain Tissue Factor”Journal of Biological Chemistry260(20):10917-10920 (1985).
Carson and Brozna, “The role of tissue factor in the production of thrombin”Blood. Coag. Fibrinol4:281-292 (1993).
Carson et al., “An Inhibitory Monoclonal Antibody Against Human Tissue Factor.”Blood70(2):490-493 (1987).
Carson et al., “Monoclonal Antibodies Against Bovine Tissue Factor, Which Block Interaction with Factor VIIa”Blood66(1):152-156 (1985).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci.USA 89:4285-4289 (May 1992).
Chothia, C. et al., “Conformations of immunoglobulin hypervariable regions”Nature342(6252):877-883 (1989).
Colman, R. W., “The Role of Plasma Proteases In Septic Shock”The New England J. of Med.320(18):1207-1209 (1989).
Creasey et al., “Tissue Factor Pathway Inhibitor Reduces Mortality fromEscherichia coliSeptic Shock”J. Clin. Invest.91:2850-2860 (1993).
Davie et al., “The Coagulation Cascade: Initiation, Maintenance, and Regulation”Biochemistry30(43):10363-10370 (1991).
De Guzman et al., “Inhibition of tissue factor or intrinsic XASE are effective antithrombotic strategies in a new model of venous thrombosis”Thrombosis and Haemostasis Abstracts from XVIth Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, Jun. 6-12, 1997, PS-1194:1-844.
Dickinson and Ruf, “Active Site Modification of Factor VIIa Affects Interactions of the Protease Domain with Tissue Factor”Journal of Biological Chemistry272(32):19875-19879 (Aug. 1997).
Dickinson et al., “Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa”Proc. Natl. Acad. SciUSA 93:14379-14384 (Dec. 1996).
Diffang et al, “Effect of Trasylol on Fibrin Deposition and Elimination in the Lungs of Rats with Intravascular Coagulation Induced by Thrombin or Thromboplastin”Thrombosis Research5:263-276 (1974).
Dittmar et al., “Influence of mutations in tissue factor on the fine specificity of macromolecular substrate activation”Biochemical Journal321(3):787-793 (1997).
Drake et al., “Functional Tissue Factor Is Entirely Cell Surface Expressed on Lipopolysaccharide-stimulated Human Blood Monocytes and a Constitutively Tissue Factor-producing Neoplastic Cell Line”Journal of Cell Biology109:389-395 (Jul. 1989).
Eaton et al., “Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule”Biochemistry25:8343-8347 (1986).
Eigenbrot et al., “X-Ray Structures of the Antigen-Binding Domains From Three Variants of Humanized Anti-p185HER2Antibody 4D5 and Comparison With Molecular Modeling”J. Mol. Bio.229:969-995 (1993).
Fiore et al., “An Unusual Antibody that Blocks Tissue Factor/Factor VIIa Function by Inhibiting Cleavage Only of Macromolecular Substrates”Blood80(12):3127-3134 (Dec. 15, 1992).
Fisher et al., “Cloning and Expression of Human Tissue Factor cDNA”Thrombosis Research48(1) :89-99 (1987).
Gast A. and T.B. Tschopp, “Inhibition of extrinsic and intrinsic thrombin generation by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma”Blood Coag. Fibrinolysis6:533-560 (1995).
Gibbs et al., “Identification of the Factor VIIa Binding Site on Tissue Factor by Homologous Loop Swap and Alanine Scanning Mutagenesis”Biochemistry33(47):14003-14010 (1994).
Golino et al., “Effects
Kirchhofer Daniel K.
Lowe David G.
Presta Leonard G.
Genentech Inc.
Morrison & Foerster / LLP
Szperka Michael
LandOfFree
Anti-tissue factor antibodies with enhanced anticoagulant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tissue factor antibodies with enhanced anticoagulant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tissue factor antibodies with enhanced anticoagulant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3990604